Provided by Tiger Trade Technology Pte. Ltd.

Atrium Therapeutics

10.36
+0.01000.10%
Post-market: 10.20-0.1600-1.54%19:30 EDT
Volume:247.50K
Turnover:2.54M
Market Cap:177.21M
PE:-2.69
High:10.41
Open:10.37
Low:10.00
Close:10.35
52wk High:16.77
52wk Low:10.00
Shares:17.11M
Float Shares:15.72M
Volume Ratio:0.39
T/O Rate:1.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8578
EPS(LYR):-3.1905
ROE:-43.98%
ROA:-399.25%
PB:0.83
PE(LYR):-3.25

Loading ...

Company Profile

Company Name:
Atrium Therapeutics
Exchange:
NASDAQ
Establishment Date:
2025
Employees:
- -
Office Location:
10578 Science Center Drive,Suite 125,San Diego,California,United States
Zip Code:
92121
Fax:
- -
Introduction:
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease is under phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of Duchenne Muscular Dystrophy, which is under phase 1/2 clinical trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy is in phase 1/2 clinical trial. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.